Code Biotherapeutics

What Code Biotherapeutics does

Code Biotherapeutics is a clinical-stage, privately held biotechnology company developing targeted non-viral gene therapies for rare and prevalent genetic diseases. The company is built around its proprietary 3DNA® platform — a multivalent synthetic DNA-based delivery vehicle engineered to overcome key limitations of viral gene therapies, including immunogenicity, gene size constraints, lack of re-dosability, off-target effects, and vector manufacturing complexity. The platform supports delivery of multiple modalities (genes, siRNA, microRNA, ASOs, gene editing constructs, and small molecules) and has demonstrated efficacy in preclinical models across brain microglia, lung endothelial cells, B/T cells, eye, muscle, pancreas, and tumor tissues, with discovery work extending into liver, ear, heart, and kidney indications.

The company's internal pipeline is led by programs in Duchenne Muscular Dystrophy (DMD) and Type 1 Diabetes (T1D), both advancing toward IND-enabling studies. Code Bio monetizes through a hybrid model: (1) upfront, milestone, and royalty payments from strategic licensing and option agreements with pharmaceutical partners — most notably a Takeda collaboration covering four rare-disease programs (liver-directed and CNS-directed) with up to $2 billion in potential total deal value; and (2) future internal product commercialization for its wholly owned rare-disease assets. Through April 2022 the company has raised approximately $85 million in venture financing ($10M seed in April 2021; $75M Series A in June 2022 led by Northpond Ventures) from a syndicate that includes Amgen Ventures, Hatteras Venture Partners, UCB Ventures, 4BIO Capital, UPMC Enterprises, CureDuchenne Ventures, JDRF T1D Fund, NEA, and Takeda Ventures, with disease-focused and pharma strategic investors reflecting the pipeline's therapeutic orientation. The company is led by an experienced management team including CEO and co-founder Brian P. McVeigh (formerly VP of Worldwide Business Development Transactions at GlaxoSmithKline) and co-founder Robert C. Getts, Ph.D. (original developer of the 3DNA platform), with offices in the Greater Philadelphia gene therapy hub.

Name

Code Biotherapeutics

Legal name

Code Biotherapeutics, Inc.

Website

https://codebiotx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Code Biotherapeutics is a clinical-stage biotech developing targeted non-viral gene therapies via its proprietary 3DNA® delivery platform for rare and prevalent genetic diseases, with lead programs in Duchenne Muscular Dystrophy and Type 1 Diabetes and a strategic partnership with Takeda.

Ownership category

akta.pro rank

Product category

Genetic Medicines / Non-Viral Gene Therapy Delivery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

akta.pro secondary industry

Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)

Keywords

• Non-viral gene therapy
• Genetic medicines delivery
• Synthetic DNA platform
• Targeted gene delivery
• Rare disease therapeutics

Headquarters

HQ city

Hatfield

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Partnering / Licensing Revenue: Code Bio generates revenue through strategic licensing and co-development agreements with pharmaceutical partners. The company receives upfront payments, near-term milestone and research funding, with eligibility for future development and commercial milestone payments plus tiered royalties. An example is the Takeda collaboration valued at up to $2 billion if all four program milestones are achieved.
2. Internal Pipeline Development: The company advances its own internal pipeline of genetic medicines targeting rare diseases (e.g., DMD, T1D) with the goal of developing and eventually commercializing proprietary therapies, with revenue expected to come from product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

Code Biotherapeutics develops and commercializes the proprietary 3DNA® platform, a multivalent synthetic DNA-based non-viral delivery system used to deliver genetic medicines (genes, RNAi, ASOs, microRNA, gene editing constructs, and small molecules) to targeted tissues. The company advances an internal pipeline led by programs in Duchenne Muscular Dystrophy (DMD) and Type 1 Diabetes (T1D), and structures licensing and co-development partnerships with pharmaceutical companies (notably Takeda) for additional rare disease programs.

Product overview

Code Biotherapeutics operates as a biotechnology company built around its proprietary 3DNA® non-viral gene delivery platform. The platform serves as the core technology enabling tissue-targeted, re-dosable delivery of genetic medicines. The company's product portfolio includes internal pipeline programs in Duchenne Muscular Dystrophy (DMD) and Type 1 Diabetes (T1D), along with partnership programs that extend the platform's capabilities for gene therapy, siRNA, microRNA, ASOs, gene editing constructs, and small drug molecules. The 3DNA platform addresses key limitations of viral-based delivery approaches and enables delivery of large genetic payloads approaching 10kb.

Differentiator

Problem solved

Functional benefit

Brands

• 3DNA®: Proprietary targeted non-viral multivalent synthetic DNA delivery platform for genetic medicines, RNAi and other modalities

Products and services

• 3DNA® Non-Viral Gene Delivery Platform

Quantifiable outcome

• 3DNA has demonstrated delivery of genes approaching 10kb with no upper limit yet reached
• +4 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• TakedaflagshipStrategic or Co-development Partner · 22 February 2022Code Bio entered a collaboration and option agreement with Takeda to leverage the 3DNA platform to design and develop gene therapies for rare disease indications. The partnership includes a liver-directed rare disease program plus CNS-directed rare disease programs. Takeda has the right to exercise options for an exclusive license for four programs. Code Bio receives double-digit million dollars in upfront, near-term milestone, and research funding payments, with potential total deal value of up to $2 billion if milestones for all four programs are achieved. Takeda and Code Bio collaborate on research up to candidate selection, after which Takeda assumes development and commercialization responsibility.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Generation Bio: Clinical-stage biotechnology company developing a non-viral gene therapy platform using closed-ended DNA (ceDNA) delivered via lipid nanoparticles. Most directly comparable to Code Bio in approach: both are non-viral delivery platform companies pursuing gene therapy for rare and prevalent genetic diseases, and both have faced scale-up and clinical translation challenges.
• Solid Biosciences: Clinical-stage gene therapy company focused on Duchenne Muscular Dystrophy and other neuromuscular diseases. Directly comparable as a DMD-targeted gene therapy developer, though using AAV delivery rather than Code Bio's non-viral 3DNA platform — illustrating both the therapeutic overlap and Code Bio's differentiated delivery modality.
• Intellia Therapeutics: Clinical-stage CRISPR/Cas9 gene editing company using lipid nanoparticle (LNP) non-viral delivery for in vivo applications including transthyretin amyloidosis and hereditary angioedema. Comparable to Code Bio as a non-viral in vivo genetic medicine platform with potential for repeat dosing across multiple tissues.
• Verve Therapeutics: Clinical-stage cardiovascular gene editing company using LNP-based in vivo delivery of base editing constructs. Comparable to Code Bio in deploying non-viral delivery for in vivo genetic medicines with the goal of one-time, durable treatments for serious diseases.
• Beam Therapeutics: Clinical-stage base editing company developing precision genetic medicines using both LNP non-viral delivery and electroporation ex vivo. Comparable to Code Bio as a multi-modality genetic medicines platform with broad therapeutic area ambition and similar early-stage clinical profile.

Broad incumbents

• Sarepta Therapeutics: Commercial-stage leader in DMD genetic medicines with Elevidys (delandistrogene moxeparvovec), an AAV-based gene therapy approved in the US. Most relevant comparable incumbent for Code Bio's lead DMD program — sets the competitive standard Code Bio must beat on safety, efficacy, and durability.
• REGENXBIO: Clinical and commercial-stage gene therapy company with a proprietary AAV delivery platform (NAV Technology) used both in its own pipeline and licensed to multiple large pharma partners. Comparable to Code Bio's 3DNA platform-licensing model and Takeda-style partner ecosystem.

Emerging players

• Editas Medicine: Clinical-stage CRISPR gene editing company developing in vivo and ex vivo therapies. Comparable as a genetic medicines platform with multi-modality potential and a similar partnership-heavy business model, though using different delivery vehicles (AAV and electroporation).
• Wave Life Sciences: Clinical-stage RNA therapeutics company using PRISM platform for stereopure oligonucleotides including siRNA and ASO modalities. Comparable to Code Bio in delivering nucleic acid-based genetic medicines with tissue-targeting and re-dosing advantages over viral vectors.
• Prime Medicine: Clinical-stage prime editing company with a broad multi-indication platform approach to genetic medicines. Comparable to Code Bio as a platform genetic medicines company with the goal of treating previously untreatable diseases through novel delivery and editing approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/CodeBioTx
• LinkedInlinkedin.com/company/code-biotherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Code Biotherapeutics